The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials
CONCLUSIONS: Current evidence does not support supplementation with resveratrol for the management of cardiometabolic risk factors in patients with T2D, MetS, and NAFLD. In the case of HbA1c, subject to the limitations such as short-term follow-up and small sample size, there was a clinically important effect. The protocol of the present systematic review was registered in Open Science Framework (https://osf.io/ake85; registration doi: 10.17605/OSF.IO/AKE85).PMID:34320173 | DOI:10.1093/ajcn/nqab250
Source: Am J Clin Nutr - Category: Nutrition Authors: Sheida Zeraattalab-Motlagh Ahmad Jayedi Sakineh Shab-Bidar Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Heart | Insulin | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Science | Urology & Nephrology